Heron Therapeutics Inc vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Heron Therapeutics Inc trades at $0.35 (market cap $61.47M), while GraniteShares 2x Long NVDA Daily ETF trades at $36.34. The key difference: GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | NVDL | |
|---|---|---|
Market Cap | $61.47M | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $1.49 | $43.02 |
52-Week Low | $0.32 | $21.76 |
Enterprise Value | $168.21M | — |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $36.00, up 4.77% in the last 24 hours. The technical outlook is bullish, supported by moving averages, though the RSI suggests mild overbought conditions. Recent corporate actions include two stock splits effective June 2026. The fund provides leveraged exposure to NVIDIA, which remains a dominant force in AI, but key financial ratios for NVDL itself are not publicly detailed as it is an ETF tracking daily returns.
The outlook for NVDL hinges on NVIDIA's performance, with bullish technicals and media sentiment pointing to potential gains, especially around earnings. However, risks include high volatility from daily leverage reset, which can amplify losses during NVIDIA downturns, as seen in past sharp declines. Investors should weigh the leveraged structure's compounding effects against NVIDIA's strong AI-driven growth trajectory.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →